Theoretical Medicine and Bioethics

, Volume 32, Issue 4, pp 229–243

The placebo phenomenon and medical ethics: Rethinking the relationship between informed consent and risk–benefit assessment

Authors

    • Department of Bioethics Clinical CenterNational Institutes of Health
  • Luana Colloca
    • Department of Bioethics Clinical CenterNational Institutes of Health
    • National Center for Complementary and Alternative MedicineNational Institutes of Health
Article

DOI: 10.1007/s11017-011-9179-8

Cite this article as:
Miller, F.G. & Colloca, L. Theor Med Bioeth (2011) 32: 229. doi:10.1007/s11017-011-9179-8

Abstract

It has been presumed within bioethics that the benefits and risks of treatments can be assessed independently of information disclosure to patients as part of the informed consent process. Research on placebo and nocebo effects indicates that this is not true for symptomatic treatments. The benefits and risks that patients experience from symptomatic treatments can be shaped powerfully by information about these treatments provided by clinicians. In this paper we discuss the implications of placebo and nocebo research for risk–benefit assessment and informed consent.

Keywords

Placebo responseNocebo effectInformed consentRisk–benefit assessment

Copyright information

© Springer Science+Business Media B.V. (outside the USA) 2011